Key patents on Glutaminyl Cyclase (QC) inhibition for the treatment of Alzheimer's disease granted in Japan
Patent grants strengthen IP position in Japan and follow issuance and grants in other important markets such as USA and Europe
HALLE/SAALE, Germany, 23 April 2015 - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), today announced that, during Q1 2015, the Japan Patent Office granted a number of important patents to the company. These are Japanese Patent nos. JP 5690463 (Use of inhibitors of glutaminyl cyclases for the treatment of Alzheimer's disease), JP 5677297 (Glutaminyl cyclase as a diagnostic/prognostic indicator for neurodegenerative diseases) and JP 5688745 (Heterocyclic inhibitors of glutaminyl cyclase, covering chemical space). In addition, a Notice of Allowance was released for Japanese patent application no. P2007-508347A (Use of inhibitors of glutaminyl cyclases for the treatment of Familial British Dementia and Familial Danish Dementia).
These grants strengthen Probiodrug's position in Japan; a key territory for developing and commercializing drugs for Alzheimer's disease. The JP 5690463, P2007-508347A and JP 5688745 grants in Japan follow other key markets where these patents are already issued or granted, including the USA and Europe. For JP 5677297, Probiodrug also has patent applications pending in a number of other jurisdictions, including the USA and Europe.
Hans-Ulrich Demuth, co-founder and former CSO of Probiodrug and a key inventor, commented: "These patent grants, together with the already granted and issued patents, document the novelty of Probiodrug's QC approach and acknowledge the high-calibre science performed at Probiodrug."
Hendrik Liebers, CFO of Probiodrug, added: "The patent portfolio of Probiodrug, with issued and granted medical use and composition of matter patents for the treatment of Alzheimer's disease by preventing pGlu-Abeta formation, provides Probiodrug a leading position in the field. In particular, any development and treatment attempts via QC inhibition in the field of Alzheimer's disease will fall under Probiodrug's broad, world-wide medical use patents."
Probiodrug previously achieved a number of medical use patents in connection with the development and commercialization of a novel antidiabetic class, the DP4 inhibitors. The basic medical use patents, now in the hands of Royalty Pharma, were originally filed by Probiodrug and are generating substantial revenues through licenses from the sales of this class of antidiabetics.
For more information, please contact:
Dr Konrad Glund, CEO
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 (0) 203 440 5653